{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T04:14:18Z","timestamp":1728101658405},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1245\/s10434-024-15789-6","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T16:02:36Z","timestamp":1723564956000},"page":"7570-7581","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining the Need for Services for Patients at High Risk of Breast Cancer at a Safety-Net Hospital: An Approach to Narrowing the Disparities Gap"],"prefix":"10.1245","volume":"31","author":[{"given":"Olivia","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Fiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Paysour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruchi","family":"Aluwalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aysia","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cletus","family":"Arciero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara R.","family":"Farley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Conyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"Postlewait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"15789_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA A Cancer J Clin. 2022;72:524\u201341.","journal-title":"CA A Cancer J Clin."},{"key":"15789_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin."},{"key":"15789_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3322\/caac.21718","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American\/black people 2022. CA Cancer J Clin. 2022;72:202\u201329.","journal-title":"CA Cancer J Clin."},{"key":"15789_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","volume":"93","author":"B Fisher","year":"2001","unstructured":"Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst. 2001;93:684\u201390.","journal-title":"J Natl Cancer Inst."},{"key":"15789_CR5","first-page":"810","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. 2020;382:810\u201321.","journal-title":"Pembrolizumab for early triple-negative breast cancer."},{"key":"15789_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"L Gianni","year":"2010","unstructured":"Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet London, Engl. 2010;375:377\u201384.","journal-title":"Lancet London, Engl."},{"key":"15789_CR7","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1002\/cncr.34391","volume":"128","author":"L Moubadder","year":"2022","unstructured":"Moubadder L, Collin LJ, Nash R, et al. Drivers of racial, regional, and socioeconomic disparities in late-stage breast cancer mortality. Cancer. 2022;128:3370\u201382.","journal-title":"Cancer"},{"key":"15789_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/bcr3429","volume":"15","author":"DN Danforth Jr","year":"2013","unstructured":"Danforth DN Jr. Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. BCR Breast Cancer Res. 2013;15:208.","journal-title":"BCR Breast Cancer Res."},{"key":"15789_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/jnci\/djaa148","volume":"113","author":"KS Albain","year":"2021","unstructured":"Albain KS, Gray RJ, Makower DF, et al. Race, ethnicity, and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial. J Natl Cancer Inst. 2021;113:390\u20139.","journal-title":"J Natl Cancer Inst."},{"key":"15789_CR10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/cncr.23568","volume":"113","author":"SG Gabram","year":"2008","unstructured":"Gabram SG, Lund MJ, Gardner J, et al. Effects of an outreach and internal navigation program on breast cancer diagnosis in an urban cancer center with a large African-American population. Cancer. 2008;113:602\u20137.","journal-title":"Cancer."},{"key":"15789_CR11","doi-asserted-by":"publisher","first-page":"e2356879","DOI":"10.1001\/jamanetworkopen.2023.56879","volume":"7","author":"JM Miller-Kleinhenz","year":"2024","unstructured":"Miller-Kleinhenz JM, Barber LE, Maliniak ML, et al. Historical redlining, persistent mortgage discrimination, and race in breast cancer outcomes. JAMA Ntwk Open. 2024;7:e2356879.","journal-title":"JAMA Ntwk Open."},{"key":"15789_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10549-024-07279-w","volume":"205","author":"LJ Collin","year":"2024","unstructured":"Collin LJ, Jones J, Nash R, Switchenko JM, Ward KC, McCullough LE. Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia. Breast Cancer Res Treat. 2024;205:609.","journal-title":"Breast Cancer Res Treat."},{"key":"15789_CR13","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1158\/2159-8290.CD-22-0138","volume":"12","author":"R Martini","year":"2022","unstructured":"Martini R, Delpe P, Chu TR, et al. African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in women of African descent. Cancer Discovery. 2022;12:2530\u201351.","journal-title":"Cancer Discovery."},{"key":"15789_CR14","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/tbj.13967","volume":"26","author":"T Sciaraffa","year":"2020","unstructured":"Sciaraffa T, Guido B, Khan SA, Kulkarni S. Breast cancer risk assessment and management programs: a practical guide. Breast J. 2020;26:1556\u201364.","journal-title":"Breast J."},{"key":"15789_CR15","doi-asserted-by":"publisher","first-page":"900","DOI":"10.6004\/jnccn.2023.0046","volume":"21","author":"TB Bevers","year":"2023","unstructured":"Bevers TB, Niell BL, Baker JL, et al. NCCN Guidelines insights: breast cancer screening and diagnosis, version 1. 2023: featured updates to the NCCN guidelines. J Natl Comp Cancer Ntwk. 2023;21:900\u20139.","journal-title":"J Natl Comp Cancer Ntwk."},{"key":"15789_CR16","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1001\/jama.2015.12783","volume":"314","author":"KC Oeffinger","year":"2015","unstructured":"Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American cancer society. JAMA. 2015;314:1599\u2013614.","journal-title":"JAMA."},{"key":"15789_CR17","unstructured":"NCCN Guidelines Version 1.2024 Breast Cancer Screening and Diagnosis. Retrieved xxxx at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast-screening.pdf."},{"key":"15789_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jacr.2023.04.002","volume":"20","author":"DL Monticciolo","year":"2023","unstructured":"Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR. J Am Coll Radiol. 2023;20:902\u201314.","journal-title":"J Am Coll Radiol."},{"key":"15789_CR19","unstructured":"NCCN Guidelines Version 2.2024 Breast Cancer Risk Reduction. Retrieved xxxx at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_risk.pdf."},{"key":"15789_CR20","unstructured":"National Accreditation Program for Breast Centers Standards. Retrieved xxxx 2024 at https:\/\/accreditation.facs.org\/accreditationdocuments\/NAPBC\/Standards\/Optimal_Resources_for_Breast_Care_2024.pdf."},{"key":"15789_CR21","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/cncr.28820","volume":"120","author":"NC Lee","year":"2014","unstructured":"Lee NC, Wong FL, Jamison PM, et al. Implementation of the national breast and cervical cancer early detection program: the beginning. Cancer. 2014;120:2540\u20138.","journal-title":"Cancer"},{"key":"15789_CR22","unstructured":"NCCN Guidelines Version 3.2024 Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Retrieved xxxx at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."},{"key":"15789_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10549-008-9926-3","volume":"113","author":"MJ Lund","year":"2009","unstructured":"Lund MJ, Trivers KF, Porter PL, et al. Race and triple-negative threats to breast cancer survival: a population-based study in Atlanta. GA Breast Cancer Res Treat. 2009;113:357\u201370.","journal-title":"GA. Breast Cancer Res Treat."},{"key":"15789_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.whi.2015.02.006","volume":"25","author":"C Farley","year":"2015","unstructured":"Farley C, Friedman D, Habtes I, et al. Screening mammography in a public hospital serving predominantly African-American women: a stage-survival-cost model. Women\u2019s Health Issues. 2015;25:322\u201330.","journal-title":"Women's Health Issues"},{"key":"15789_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10549-007-9675-8","volume":"109","author":"MJ Lund","year":"2008","unstructured":"Lund MJ, Brawley OP, Ward KC, Young JL, Gabram SS, Eley JW. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2008;109:545\u201357.","journal-title":"Breast Cancer Res Treat."},{"key":"15789_CR26","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/sim.1668","volume":"23","author":"J Tyrer","year":"2004","unstructured":"Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111\u201330.","journal-title":"Stat Med."},{"key":"15789_CR27","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1002\/cncr.33767","volume":"127","author":"AW Kurian","year":"2021","unstructured":"Kurian AW, Hughes E, Simmons T, et al. Performance of the IBIS\/Tyrer\u2013Cuzick model of breast cancer risk by race and ethnicity in the Women\u2019s Health Initiative. Cancer. 2021;127:3742\u201350.","journal-title":"Cancer."},{"key":"15789_CR28","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1200\/JCO.21.01236","volume":"39","author":"JR Palmer","year":"2021","unstructured":"Palmer JR, Zirpoli G, Bertrand KA, et al. A validated risk prediction model for breast cancer in US black women. J Clin Oncol. 2021;39:3866\u201377.","journal-title":"J Clin Oncol."},{"key":"15789_CR29","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/cancers15041124","volume":"15","author":"LS Velentzis","year":"2023","unstructured":"Velentzis LS, Freeman V, Campbell D, et al. Breast cancer risk assessment tools for stratifying women into risk groups: a systematic review. Cancers. 2023;15:1124.","journal-title":"Cancers"},{"key":"15789_CR30","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1016\/j.clbc.2019.02.014","volume":"19","author":"K Wernke","year":"2019","unstructured":"Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C. Impact of implementing B-RST(TM) to screen for hereditary breast and ovarian cancer on risk perception and genetic counseling uptake among women in an academic safety net hospital. Clin Breast Cancer. 2019;19:e547\u201355.","journal-title":"Clin Breast Cancer"},{"key":"15789_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/jbi\/wbad092","volume":"6","author":"WT Rahman","year":"2024","unstructured":"Rahman WT, Gerard S, Grundlehner P, et al. Outcomes of high-risk breast MRI screening in women without prior history of breast cancer: effectiveness data from a tertiary care center. J Breast Imaging. 2024;6:53\u201363.","journal-title":"J Breast Imaging"},{"key":"15789_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1586\/14737140.9.1.51","volume":"9","author":"VG Vogel","year":"2009","unstructured":"Vogel VG. The NSABP study of tamoxifen and raloxifene (STAR) trial. Exp Rev Anticancer Ther. 2009;9:51\u201360.","journal-title":"Exp Rev Anticancer Ther."},{"key":"15789_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","volume":"395","author":"J Cuzick","year":"2020","unstructured":"Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet London Engl. 2020;395:117\u201322.","journal-title":"Lancet London Engl."},{"key":"15789_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.7150\/jca.6481","volume":"4","author":"F Cadiz","year":"2013","unstructured":"Cadiz F, Kuerer HM, Puga J, Camacho J, Cunill E, Arun B. Establishing a program for individuals at high risk for breast cancer. J Cancer. 2013;4:433\u201346.","journal-title":"J Cancer."},{"key":"15789_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-018-05116-5","volume":"175","author":"A Weiss","year":"2019","unstructured":"Weiss A, Grossmith S, Cutts D, et al. Customized breast cancer risk assessment in an ambulatory clinic: a portal for identifying women at risk. Breast Cancer Res Treat. 2019;175:229\u201337.","journal-title":"Breast Cancer Res Treat."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15789-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15789-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15789-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T12:06:29Z","timestamp":1728043589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15789-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["15789"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15789-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}